Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Observational
Observational Model: Cohort, Time Perspective: Prospective
frequency of "actionable" oncogenic mutations
"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.
1 year
No
David Hyman, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
12-245
NCT01775072
January 2013
January 2015
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |